Arvinas Holding Company (ARVN) Stock Forecast & Price Target

Compare

1,041 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARVN Analyst Ratings

Moderate Buy

8 Buy

4 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Arvinas

Holding Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARVN Stock 12 Month Forecast

Average Price Target

$16.44

▲(23.61% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Arvinas Holding Company in the last 3 months. The average price target is $16.44 with a high forecast of $20.00 and a low forecast of $11.00. The average price target represents a 23.61% change from the last price of $13.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","21":"$21","9.75":"$9.75","13.5":"$13.5","17.25":"$17.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,9.75,13.5,17.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.83,14.304615384615385,14.77923076923077,15.253846153846155,15.728461538461538,16.203076923076924,16.677692307692308,17.152307692307694,17.626923076923077,18.10153846153846,18.576153846153847,19.05076923076923,19.525384615384617,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.83,14.03076923076923,14.231538461538461,14.432307692307692,14.633076923076924,14.833846153846155,15.034615384615385,15.235384615384616,15.436153846153847,15.636923076923077,15.837692307692308,16.03846153846154,16.239230769230772,{"y":16.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.83,13.612307692307692,13.394615384615385,13.176923076923076,12.95923076923077,12.741538461538461,12.523846153846154,12.306153846153846,12.088461538461539,11.87076923076923,11.653076923076924,11.435384615384615,11.217692307692307,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.61,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.23,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 52, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 62, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.81,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 52, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.83,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$16.44

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Srikripa Devarakonda

Truist Financial

―

Hold

―

Reiterated

02/26/26

Analysts Conflicted on These Healthcare Names: Medline, Inc. Class A (NASDAQ: MDLN), MannKind (NASDAQ: MNKD) and Arvinas Holding Company (NASDAQ: ARVN)

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

02/26/26

Analysts Are Neutral on These Healthcare Stocks: Innoviva (INVA), Arvinas Holding Company (ARVN)

Etzer Darout

Barclays

$18

Buy

35.34%

Upside

Reiterated

02/25/26

Barclays Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

Andrew Fein

H.C. Wainwright

$18

Buy

35.34%

Upside

Reiterated

02/25/26

Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (NASDAQ: AKBA), Idexx Laboratories (NASDAQ: IDXX) and Arvinas Holding Company (NASDAQ: ARVN)

Derek Archila

Wells Fargo

$15

Buy

12.78%

Upside

Reiterated

02/25/26

Arvinas Holding Company (ARVN) Receives a Buy from Wells Fargo

Sudan Loganathan

Stephens

$18

Buy

35.34%

Upside

Reiterated

02/25/26

Stephens Sticks to Its Buy Rating for Arvinas Holding Company (ARVN)

Edward Tenthoff

Piper Sandler

$16→$20

Buy

50.38%

Upside

Reiterated

02/25/26

Arvinas price target raised to $20 from $16 at Piper SandlerArvinas price target raised to $20 from $16 at Piper Sandler

Robert Driscoll

Wedbush

$9→$11

Hold

-17.29%

Downside

Reiterated

02/25/26

Arvinas price target raised to $11 from $9 at WedbushArvinas price target raised to $11 from $9 at Wedbush

Jonathan Miller

Evercore ISI

$14→$19

Buy

42.86%

Upside

Reiterated

02/25/26

Arvinas price target raised to $19 from $14 at Evercore ISIArvinas price target raised to $19 from $14 at Evercore ISI

Tyler Van Buren

TD Cowen

―

Hold

―

Reiterated

02/24/26

Balancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts

Jeet Mukherjee

BTIG

$14

Buy

5.26%

Upside

Reiterated

02/24/26

Arvinas: Strong Pipeline Momentum, De-Risked Cash Runway, and Attractive Risk‑Reward Support Buy Rating

Yigal Nochomovitz

Citi

$15

Buy

12.78%

Upside

Reiterated

02/20/26

Citi Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

Tazeen Ahmad

Bank of America Securities

$12

Hold

-9.77%

Downside

Reiterated

11/05/25

Bank of America Securities Sticks to Their Hold Rating for Arvinas Holding Company (ARVN)

Paul Choi

Goldman Sachs

$8→$6

Sell

-54.89%

Downside

Downgraded

10/16/25

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN), Sarepta Therapeutics (NASDAQ: SRPT) and PTC Therapeutics (NASDAQ: PTCT)

Terence Flynn

Morgan Stanley

$10

Hold

-24.81%

Downside

Reiterated

09/22/25

Arvinas Holding: Strategic Shifts and Cost Optimization Amidst Competitive SERD Landscape

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Srikripa Devarakonda

Truist Financial

―

Hold

―

Reiterated

02/26/26

Analysts Conflicted on These Healthcare Names: Medline, Inc. Class A (NASDAQ: MDLN), MannKind (NASDAQ: MNKD) and Arvinas Holding Company (NASDAQ: ARVN)

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

02/26/26

Analysts Are Neutral on These Healthcare Stocks: Innoviva (INVA), Arvinas Holding Company (ARVN)

Etzer Darout

Barclays

$18

Buy

35.34%

Upside

Reiterated

02/25/26

Barclays Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

Andrew Fein

H.C. Wainwright

$18

Buy

35.34%

Upside

Reiterated

02/25/26

Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (NASDAQ: AKBA), Idexx Laboratories (NASDAQ: IDXX) and Arvinas Holding Company (NASDAQ: ARVN)

Derek Archila

Wells Fargo

$15

Buy

12.78%

Upside

Reiterated

02/25/26

Arvinas Holding Company (ARVN) Receives a Buy from Wells Fargo

Sudan Loganathan

Stephens

$18

Buy

35.34%

Upside

Reiterated

02/25/26

Stephens Sticks to Its Buy Rating for Arvinas Holding Company (ARVN)

Edward Tenthoff

Piper Sandler

$16→$20

Buy

50.38%

Upside

Reiterated

02/25/26

Arvinas price target raised to $20 from $16 at Piper SandlerArvinas price target raised to $20 from $16 at Piper Sandler

Robert Driscoll

Wedbush

$9→$11

Hold

-17.29%

Downside

Reiterated

02/25/26

Arvinas price target raised to $11 from $9 at WedbushArvinas price target raised to $11 from $9 at Wedbush

Jonathan Miller

Evercore ISI

$14→$19

Buy

42.86%

Upside

Reiterated

02/25/26

Arvinas price target raised to $19 from $14 at Evercore ISIArvinas price target raised to $19 from $14 at Evercore ISI

Tyler Van Buren

TD Cowen

―

Hold

―

Reiterated

02/24/26

Balancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts

Jeet Mukherjee

BTIG

$14

Buy

5.26%

Upside

Reiterated

02/24/26

Arvinas: Strong Pipeline Momentum, De-Risked Cash Runway, and Attractive Risk‑Reward Support Buy Rating

Yigal Nochomovitz

Citi

$15

Buy

12.78%

Upside

Reiterated

02/20/26

Citi Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

Tazeen Ahmad

Bank of America Securities

$12

Hold

-9.77%

Downside

Reiterated

11/05/25

Bank of America Securities Sticks to Their Hold Rating for Arvinas Holding Company (ARVN)

Paul Choi

Goldman Sachs

$8→$6

Sell

-54.89%

Downside

Downgraded

10/16/25

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN), Sarepta Therapeutics (NASDAQ: SRPT) and PTC Therapeutics (NASDAQ: PTCT)

Terence Flynn

Morgan Stanley

$10

Hold

-24.81%

Downside

Reiterated

09/22/25

Arvinas Holding: Strategic Shifts and Cost Optimization Amidst Competitive SERD Landscape

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arvinas Holding Company

3 Months

xxx

Success Rate

6/12 ratings generated profit

Average Return

+5.65%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +5.65% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

9/17 ratings generated profit

Average Return

+9.36%

reiterated a buy rating 2 days ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +9.36% per trade.

2 Years

xxx

Success Rate

8/12 ratings generated profit

Average Return

+18.92%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +18.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARVN Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARVN has received 13 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. ARVN average Analyst price target in the past 3 months is 16.44.

Each month's total comprises the sum of three months' worth of ratings.

ARVN Financial Forecast

ARVN Earnings Forecast

Next quarter’s earnings estimate for ARVN is -$0.93 with a range of -$1.21 to -$0.71. The previous quarter’s EPS was -$1.10. ARVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ARVN has Performed in-line its overall industry.

ARVN Sales Forecast

Next quarter’s sales forecast for ARVN is $17.93M with a range of $400.00K to $35.30M. The previous quarter’s sales results were $9.50M. ARVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ARVN has Performed in-line its overall industry.

ARVN Stock Forecast FAQ

What is ARVN’s average 12-month price target, according to analysts?

Based on analyst ratings, Arvinas Holding Company’s 12-month average price target is 16.44.

What is ARVN’s upside potential, based on the analysts’ average price target?

Arvinas Holding Company has 23.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARVN a Buy, Sell or Hold?

Arvinas Holding Company has a consensus rating of Moderate Buy which is based on 8 buy ratings, 4 hold ratings and 0 sell ratings.

What is Arvinas Holding Company’s price target?

The average price target for Arvinas Holding Company is 16.44. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $11.00. The average price target represents 23.61% Increase from the current price of $13.3.

What do analysts say about Arvinas Holding Company?

Arvinas Holding Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of ARVN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Arvinas Holding Company (ARVN) Stock Forecast & Price Target

ARVN Analyst Ratings

ARVN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arvinas Holding Company

ARVN Analyst Recommendation Trends

ARVN Financial Forecast

ARVN Earnings Forecast

ARVN Sales Forecast

ARVN Stock Forecast FAQ

Detailed List of Analyst Forecasts